Table 3

Oral anticoagulant treatment of patients with cardioembolic stroke with unchanged or reassigned subtype

TreatmentConsistent CE* (n=282)Centrally reassigned CE† (n=262)Newly diagnosed CE‡ (n=447)
With indication§
n=270
Without indication n=12P valueWith indication§
n=161
Without indication n=101P valueWith indication§
n=300
Without indication n=147P value
In-hospital anticoagulant151 (55.9%)4 (33.3%)0.14686 (53.4%)18 (17.8%)<0.000182 (27.3%)12 (8.2%)<0.0001
 Warfarin89/151 to 58.9%3/4 to 75.0%0.64746/86 to 53.5%5/18 to 27.8%0.06926/82 to 31.7%1/12 to 8.3%0.169
 LWHP80/151 to 53.0%1/4 to 25.0%0.34949/86 to 57.0%9/18 to 50.0%0.61143/82 to 52.4%8/12 to 66.7%0.537
 Heparin1/151 to 0.7%0/4 to 0%1.0004/18 to 22.2%0/86 to 0%<0.0011/82 to 1.2%0/12 to 0%1.000
 Rivaroxaban9/151 to 6.0%0/4 to 0%1.0002/86 to 2.3%0/18 to 0%1.0002/82 to 2.4%0/12 to 0%1.000
 Dabigatran22/151 to 14.6%1/4 to 25.0%0.4786/86 to 7.0%1/18 to 5.6%1.0005/82 to 6.1%0/12 to 0%1.000
 Apixaban0/151 to 0%0/4 to 0%NE0/86 to 0%0/18 to 0%NE0/82 to 0%0/12 to 0%NE
 Others4/151 to 2.7%0/4 to 0%1.0002/86 to 2.3%1/18 to 5.6%0.43811/82 to 13.4%3/12 to 25.0%0.379
Treatment Consistent CE¶ (n=283) Centrally reassigned CE** (n=261) Newly diagnosed CE†† (n=448)
With indication§ n=271 Without indication n=12 P value With indication§ n=157 Without indication n=104 P value With indication§ n=300 Without indication n=148 P value
Discharge anticoagulant139 (51.3%)4 (33.3%)0.25266 (42.0%)8 (7.7%)<0.000146 (15.3%)2 (1.4%)<0.0001
 Warfarin103/139 to 74.1%3/4 to 75.0%1.00053/66 to 80.3%7/8 to 87.5%1.00033/46 to 71.7%1/2 to 50.0%0.503
 LWHP0/139 to 0%0/4 to 0%NE2/66 to 3.0%1/8 to 12.5%0.2942/46 to 4.4%1/2 to 50.0%0.122
 Heparin0/139 to 0%0/4 to 0%NE0/66 to 0%0/8 to 0%NE0/46 to 0%0/2 to 0%NE
 Rivaroxaban8/139 to 5.8%0/4 to 0%1.0004/66 to 6.1%1/8 to 12.5%0.4454/46 to 8.7%0/2 to 0%1.000
 Dabigatran27/139 to 19.4%1/4 to 25.0%1.0007/66 to 10.6%0/8 to 0%1.0007/46 to 15.2%0/2 to 0%1.000
 Apixaban0/139 to 0%0/4 to 0%NE0/66 to 0%0/8 to 0%NE0/46 to 0%0/2 to 0%NE
 Others1/139 to 0.7%0/4 to 0%1.0000/66 to 0%0/8 to 0%NE0/46 to 0%0/2 to 0%NE
  • *Missing data of two patients.

  • †Missing data of four patients.

  • ‡Missing data of two patients.

  • §Indications of oral anticoagulation treatment included mechanical prosthetic valve, mitral stenosis with atrial fibrillation, atrial fibrillation, left atrial/atrial appendage thrombus, left ventricular thrombus and atrial flutter.

  • ¶Missing data of one patient.

  • **Missing data of five patients.

  • ††Missing data of one patient.

  • CE, cardioembolism; LWHP, low molecular weight heparin; NE, not estimable.